Cullinan Associates Inc. Sells 13,300 Shares of Boston Scientific Corporation $BSX

Key Points

• Cullinan Associates Inc. reduced its stake in Boston Scientific by 51.8%, selling 13,300 shares during the second quarter, leaving the firm with 12,400 shares valued at approximately $1.33 million.
• Institutional investors and hedge funds own 89.07% of Boston Scientific's stock, with notable increases in holdings from firms like Vanguard Group Inc. and Price T Rowe Associates Inc. during the last quarter.
• Boston Scientific recently reported earnings of $0.75 EPS for the last quarter, exceeding estimates, and has set its Q3 2025 earnings guidance between 0.700 and 0.720 EPS.

Cullinan Associates Inc. cut its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 51.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,400 shares of the medical equipment provider's stock after selling 13,300 shares during the quarter. Cullinan Associates Inc.'s holdings in Boston Scientific were worth $1,332,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock valued at $250,757,000 after purchasing an additional 1,536,663 shares in the last quarter. Swedbank AB boosted its stake in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock valued at $302,816,000 after purchasing an additional 1,505,019 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $97.30 on Monday. The company has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $102.93 and a 200-day moving average of $102.06.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BSX shares. Erste Group Bank downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday. Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an "overweight" rating in a research note on Thursday. Wells Fargo & Company raised their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and a consensus target price of $120.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.